Organogenesis Holdings Inc
NASDAQ:ORGO

Watchlist Manager
Organogenesis Holdings Inc Logo
Organogenesis Holdings Inc
NASDAQ:ORGO
Watchlist
Price: 4.05 USD 0.75% Market Closed
Market Cap: 536.9m USD
Have any thoughts about
Organogenesis Holdings Inc?
Write Note

Organogenesis Holdings Inc
Other

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Organogenesis Holdings Inc
Other Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other CAGR 3Y CAGR 5Y CAGR 10Y
Organogenesis Holdings Inc
NASDAQ:ORGO
Other
-$1.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other
-$100m
CAGR 3-Years
45%
CAGR 5-Years
22%
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Other
-$5.7B
CAGR 3-Years
-238%
CAGR 5-Years
-114%
CAGR 10-Years
-4%
Amgen Inc
NASDAQ:AMGN
Other
-$127m
CAGR 3-Years
-6%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other
-$398.9m
CAGR 3-Years
-39%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other
-$1.3B
CAGR 3-Years
-38%
CAGR 5-Years
-53%
CAGR 10-Years
N/A
No Stocks Found

Organogenesis Holdings Inc
Glance View

Market Cap
536.9m USD
Industry
Biotechnology

Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.

ORGO Intrinsic Value
3.14 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Organogenesis Holdings Inc's Other?
Other
-1.2m USD

Based on the financial report for Sep 30, 2024, Organogenesis Holdings Inc's Other amounts to -1.2m USD.

What is Organogenesis Holdings Inc's Other growth rate?
Other CAGR 1Y
-256%

Over the last year, the Other growth was -256%.

Back to Top